Abstract

PurposeThe most important HLA-independent factor for the selection of cord blood units (CBU) for hematopoietic stem cell transplantation is the total nucleated cell (TNC) count over 150 × 107 as a surrogate marker for stem cell content. The purpose of this prospective study was to define prenatal clinical predictors for TNC count that would help to identify successful CBU donors before the onset of active labor.MethodsThis was a prospective analysis of 594 CBUs, collected from all eligible term singleton pregnancies at Basel University Hospital between 4/2015 and 9/2016 analyzing several maternal and fetal factors. The impact of these factors on TNC count (< 150 × 107 cells vs. ≥ 150 × 107 cells) of the CBUs was modeled in a multivariate analysis.ResultsA total of 114 (19.2%) CBUs had a TNC count of ≥ 150 × 107. In a ROC analysis there was no significant difference between the AUC of all prenatal factors (AUC 0.62) and estimated fetal birth weight by ultrasound alone (AUC 0.62). For women planning a trial of labor a recruitment cut-off at an estimated birth weight of 3300 g would allow 72.6% of all donors with sufficient TNC count to be recruited and 22.8% of all collected CBUs would have a sufficient TNC count for banking. For women planning for elective CS a cut-off of 3400 g would allow 71.4% of all donors with sufficient TNC count to be recruited and 22.7% of all collected CBUs would have sufficient TNC count for banking.ConclusionThe estimated fetal birth weight within 2 weeks of delivery by ultrasound as single parameter can be considered at the time of recruitment to estimate the chances of a successful CBU donation.

Highlights

  • Once considered a waste product discarded with the placenta, umbilical cord blood is commonly used as a source of potentially life-saving hematopoietic stem cells used in the treatment of malignant and nonmalignant hematologic and immunologic diseases in the absence of a matched sibling or unrelated donor [1]

  • The mean total nucleated cell (TNC) count within the study group was 95.8 × 107 cells

  • Our study demonstrates that it can be used for prediction of stem cell content even tough random errors of fetal weight estimation are mostly reported to be larger than 7% [17]

Read more

Summary

Introduction

Once considered a waste product discarded with the placenta, umbilical cord blood is commonly used as a source of potentially life-saving hematopoietic stem cells used in the treatment of malignant and nonmalignant hematologic and immunologic diseases in the absence of a matched sibling or unrelated donor [1]. Compared to hematopoietic stem cells from bone marrow, CBU has several advantages: rapid accessibility due Archives of Gynecology and Obstetrics (2021) 304:377–384 to the possibility of cryopreserving fully tested and human leucocyte antigen (HLA)-typed units, lowered risk of and less severe acute and chronic graft-versus-host disease, reduced likelihood of transmitting infections, increased ethnic representation and risk- and pain-free collection [5]. The most important disadvantage of umbilical cord blood is the limited number of stem cells in the CBU that typically are around ten times lower than in bone marrow. Only units with a sufficient count will be used for hematopoietic stem cell transplantation [6]

Objectives
Methods
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call